|
Jana Pelouchová director of the Czech CML patient group "Diagnoza CML" discusses some of the barriers to patient participation in clinical trials and offers the patients perspective on these issues. Access to information, informed consent, mobility issues, travel expenses and language barriers are identified as the main points that must be addressed to increase the number of patients taking part in clinical trials. It is essential that patient advocate groups work together to find the most effective way to let patients know about clinical trials and that "informed consent" should be communicated in language that is much easier to understand by patients. A number of patients are also put off from entering clinical trials by the cost associated with travelling to clinical trials or by the language barrier that must be overcome when enrolling in trials outside their own country. Ms Pelouchová talks about this and also stresses the importance of taking the patients' perspective into account when designing clinical trials and making decisions regarding treatment.
|
Video Length: 0
Date Found: December 03, 2010
Date Produced:
|
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line ...
|
www.ecancer.tv |
March 01, 2011
The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and ...
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.
|
www.ecancer.tv |
March 01, 2011
Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib ...
|
www.ecancer.tv |
February 23, 2011
Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular ...
|
|
|
|
|
|
Featured Content
Featuring websites that enhance the internet user’s experience.
|